Related Experiment Video
Updated: Mar 8, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
24.1K
Intralesional Injection of OK-432 in Cystic Hygroma.
M Hazim1, S S Moses2, I P Tan2
1University Malaysia Sarawak (UNIMAS), Department of ORL-HNS, Jalan Datuk Mohd Musa, 94300 Kota Samarahan, Sarawak Malaysia. ingptang@yahoo.com.
The Medical Journal of Malaysia
|January 15, 2017
Summary
Intralesional OK-432 injections offer a safe and effective treatment for cystic hygroma, leading to significant shrinkage in most patients. This method avoids surgical complications and promotes lymphatic malformation resolution.
Area of Science:
- Medical Science
- Pediatric Surgery
- Lymphatic System Research
Background:
- Lymphangiomas, or cystic hygromas, are congenital lymphatic malformations.
- Spontaneous resolution can occur due to infection or irritants.
- Intralesional OK-432 (Picibanil) is emerging as a safe alternative to surgery for these conditions.
Purpose of the Study:
- To evaluate the clinical outcomes of cystic hygroma treatment using intralesional OK-432 injections.
- To assess the safety and efficacy of OK-432 in pediatric patients with cystic hygroma.
Main Methods:
- Six patients with cystic hygroma received intralesional OK-432 injections between 2011 and 2013.
- Clinical and radiological assessments (ultrasound, CT, MRI) were performed pre- and post-treatment.
- Treatment response was categorized as total, marked (>50%), slight (<50%) shrinkage, or non-responsive.
Main Results:
- A mean follow-up of 12 months was recorded.
- One patient achieved total shrinkage, three showed marked shrinkage, and one had slight shrinkage.
- One patient was non-responsive; no serious complications or adverse effects were reported.
Conclusions:
- Intralesional OK-432 injection is a safe and effective treatment option for cystic hygroma.
- This therapeutic approach offers a viable alternative to surgical interventions for lymphatic malformations.
